



1
2

3 451209/Issued: May 2010

4 **HEPARIN SODIUM**

5 *INJECTION, USP*

6 Rx only

7

8 DERIVED FROM PORCINE INTESTINAL MUCOSA.


9 Available as: Preservative Free **or** Contains Benzyl Alcohol **or** Parabens

10 **DESCRIPTION:**

11 Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called
12 glycosaminoglycans, having anticoagulant properties. Although others may be present, the
13 main sugars occurring in heparin are: (1) α -L-iduronic acid 2-sulfate, (2) 2-deoxy-2-
14 sulfamino- α -D-glucose 6-sulfate, (3) β -D-glucuronic acid, (4) 2-acetamido-2-deoxy- α -D-
15 glucose and (5) α -L-iduronic acid. These sugars are present in decreasing amounts, usually
16 in the order (2)> (1)> (4)> (3)> (5), and are joined by glycosidic linkages, forming polymers
17 of varying sizes. Heparin is strongly acidic because of its content of covalently linked sulfate
18 and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are
19 partially replaced by sodium ions.

20 Heparin Sodium Injection, USP is a sterile solution of heparin sodium derived from
21 porcine intestinal mucosa, standardized for anticoagulant activity, in water for injection. It is
22 to be administered by intravenous or deep subcutaneous routes. The potency is determined
23 by a biological assay using a USP reference standard based on units of heparin activity per
24 milligram.

1 Structure of Heparin Sodium (representative subunits):



2

3

4 Heparin Sodium Injection, USP (porcine), preservative free, is available as follows:

5 Each mL of the 1,000 Units per mL preparation contains: 1,000 USP Heparin Units

6 (porcine); 9 mg sodium chloride; Water for Injection q.s. Made isotonic with sodium

7 chloride. Hydrochloric acid and/or sodium hydroxide may have been added for pH

8 adjustment (5.0-7.5).

9 Heparin Sodium Injection, USP (porcine), preserved with benzyl alcohol, is available

10 as follows:

11 Each mL of the 5,000 Units per mL preparation contains: 5,000 USP Heparin Units

12 (porcine); 6 mg sodium chloride; 15 mg benzyl alcohol (as a preservative); Water for

13 Injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added for pH

14 adjustment (5.0-7.5).

15 Heparin Sodium Injection, USP (porcine), preserved with parabens, is available as

16 follows:

17 Each mL of the 1,000 Units per mL preparation contains: 1,000 USP Heparin Units

18 (porcine); 9 mg sodium chloride; 1.5 mg methylparaben; 0.15 mg propylparaben; Water for

19 Injection q.s. Made isotonic with sodium chloride. Hydrochloric acid and/or sodium

20 hydroxide may have been added for pH adjustment (5.0-7.5).

1 Each mL of the 5,000 Units per mL preparation contains: 5,000 USP Heparin Units
2 (porcine); 5 mg sodium chloride; 1.5 mg methylparaben; 0.15 mg propylparaben; Water for
3 Injection q.s. Made isotonic with sodium chloride. Hydrochloric acid and/or sodium
4 hydroxide may have been added for pH adjustment (5.0-7.5).

5 Each mL of the 10,000 Units per mL preparation contains: 10,000 USP Heparin Units
6 (porcine); 1.5 mg methylparaben; 0.15 mg propylparaben; Water for Injection q.s.
7 Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (5.0-
8 7.5).

9 Each mL of the 20,000 Units per mL preparation contains: 20,000 USP Heparin Units
10 (porcine); 1.5 mg methylparaben; 0.15 mg propylparaben; Water for Injection q.s.
11 Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment (5.0-
12 7.5).

13 **CLINICAL PHARMACOLOGY:**

14 Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots
15 both *in vitro* and *in vivo*. Heparin acts at multiple sites in the normal coagulation system.
16 Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit
17 thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin
18 to thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit
19 further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to
20 fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation
21 of the fibrin stabilizing factor.

22 Bleeding time is usually unaffected by heparin. Clotting time is prolonged by full
23 therapeutic doses of heparin; in most cases, it is not measurably affected by low doses of

1 heparin.

2 Patients over 60 years of age, following similar doses of heparin, may have higher
3 plasma levels of heparin and longer activated partial thromboplastin times (APTTs)
4 compared with patients under 60 years of age.

5 Peak plasma levels of heparin are achieved two to four hours following subcutaneous
6 administration, although there are considerable individual variations. Loglinear plots of
7 heparin plasma concentrations with time, for a wide range of dose levels, are linear, which
8 suggests the absence of zero order processes. Liver and the reticuloendothelial system are
9 the sites of biotransformation. The biphasic elimination curve, a rapidly declining alpha
10 phase ($t_{1/2} = 10$ minutes) and after the age of 40 a slower beta phase, indicates uptake in
11 organs. The absence of a relationship between anticoagulant half-life and concentration half-
12 life may reflect factors such as protein binding of heparin.

13 Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

14 **INDICATIONS AND USAGE:**

15 Heparin Sodium Injection is indicated for:

16 Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its
17 extension;

18 Low-dose regimen for prevention of postoperative deep venous thrombosis and
19 pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for
20 other reasons, are at risk of developing thromboembolic disease (see **DOSAGE AND**
21 **ADMINISTRATION**);

22 Prophylaxis and treatment of pulmonary embolism;

23 Atrial fibrillation with embolization;

1 Diagnosis and treatment of acute and chronic consumptive coagulopathies
2 (disseminated intravascular coagulation);

3 Prevention of clotting in arterial and cardiac surgery;

4 Prophylaxis and treatment of peripheral arterial embolism.

5 Heparin may also be employed as an anticoagulant in blood transfusions,
6 extracorporeal circulation, and dialysis procedures and in blood samples for laboratory
7 purposes.

8 **CONTRAINDICATIONS:**

9 Heparin sodium should NOT be used in patients with the following conditions:

10 Severe thrombocytopenia;

11 When suitable blood coagulation tests, e.g., the whole blood clotting time, partial
12 thromboplastin time, etc., cannot be performed at appropriate intervals (this contraindication
13 refers to full-dose heparin; there is usually no need to monitor coagulation parameters in
14 patients receiving low-dose heparin);

15 An uncontrollable active bleeding state (see **WARNINGS**), except when this is due
16 to disseminated intravascular coagulation.

17 ***Pregnancy, Nursing Mothers, and Pediatric Use***

18 Do not administer Heparin Sodium Injection, USP (porcine), preserved with benzyl alcohol
19 to neonates, infants, pregnant women, or nursing mothers (see **PRECAUTIONS**,
20 ***Pregnancy, Nursing Mothers, and Pediatric Use***). Benzyl alcohol has been associated with
21 serious adverse events and death, particularly in pediatric patients. Heparin Sodium
22 Injection, USP (porcine), preservative free, when indicated, should be used in these
23 populations.

1 **WARNINGS:**

2 Heparin is not intended for intramuscular use.

3 ***Fatal Medication Errors***

4 Do not use Heparin Sodium Injection as a “catheter lock flush” product. Heparin Sodium
5 Injection is supplied in vials containing various strengths of heparin, including vials that
6 contain a highly concentrated solution of 10,000 units in 1 mL. Fatal hemorrhages have
7 occurred in pediatric patients due to medication errors in which 1 mL Heparin Sodium
8 Injection vials were confused with 1 mL “catheter lock flush” vials. Carefully examine all
9 Heparin Sodium Injection vials to confirm the correct vial choice prior to administration of
10 the drug.

11 ***Hypersensitivity***

12 Patients with documented hypersensitivity to heparin should be given the drug only in clearly
13 life-threatening situations (see **ADVERSE REACTIONS, *Hypersensitivity***).

14 ***Hemorrhage***

15 Hemorrhage can occur at virtually any site in patients receiving heparin. An unexplained fall
16 in hematocrit, fall in blood pressure or any other unexplained symptom should lead to serious
17 consideration of a hemorrhagic event.

18 Heparin sodium should be used with extreme caution in disease states in which there
19 is increased danger of hemorrhage. Some of the conditions in which increased danger of
20 hemorrhage exists are:

21

22 ***Cardiovascular***—Subacute bacterial endocarditis, severe hypertension.

23

24 ***Surgical***—During and immediately following (a) spinal tap or spinal anesthesia or (b) major

1 surgery, especially involving the brain, spinal cord, or eye.

2
3 *Hematologic*—Conditions associated with increased bleeding tendencies, such as

4 hemophilia, thrombocytopenia and some vascular purpuras.

5
6 *Gastrointestinal*—Ulcerative lesions and continuous tube drainage of the stomach or small

7 intestine.

8
9 *Other*—Menstruation, liver disease with impaired hemostasis.

10 ***Coagulation Testing***

11 When heparin sodium is administered in therapeutic amounts, its dosage should be regulated

12 by frequent blood coagulation tests. If the coagulation test is unduly prolonged or if

13 hemorrhage occurs, heparin sodium should be promptly discontinued (see

14 **OVERDOSAGE**).

15 ***Thrombocytopenia***

16 Thrombocytopenia has been reported to occur in patients receiving heparin with a reported

17 incidence of up to 30%. Platelet counts should be obtained at baseline and periodically

18 during heparin administration. Mild thrombocytopenia (count greater than 100,000/mm³)

19 may remain stable or reverse even if heparin is continued. However, thrombocytopenia of

20 any degree should be monitored closely. If the count falls below 100,000/mm³ or if recurrent

21 thrombosis develops (see **Heparin-induced Thrombocytopenia and Heparin-induced**

22 **Thrombocytopenia and Thrombosis**), the heparin product should be discontinued, and, if

23 necessary, an alternative anticoagulant administered.

24 ***Heparin-induced Thrombocytopenia (HIT) and Heparin-induced Thrombocytopenia and***

25 ***Thrombosis (HITT)***

1 **Heparin-induced Thrombocytopenia (HIT) is a serious antibody-mediated reaction**
2 **resulting from irreversible aggregation of platelets. HIT may progress to the**
3 **development of venous and arterial thromboses, a condition referred to as Heparin-**
4 **induced Thrombocytopenia and Thrombosis (HITT). Thrombotic events may also be**
5 **the initial presentation for HITT. These serious thromboembolic events include deep**
6 **vein thrombosis, pulmonary embolism, cerebral vein thrombosis, limb ischemia, stroke,**
7 **myocardial infarction, mesenteric thrombosis, renal arterial thrombosis, skin necrosis,**
8 **gangrene of the extremities that may lead to amputation, and possibly death.**
9 **Thrombocytopenia of any degree should be monitored closely. If the platelet count falls**
10 **below 100,000/mm³ or if recurrent thrombosis develops, the heparin product should be**
11 **promptly discontinued and alternative anticoagulants considered, if patients require**
12 **continued anticoagulation.**

13 ***Delayed Onset of HIT and HITT***

14 Heparin-induced Thrombocytopenia and Heparin-induced Thrombocytopenia and
15 Thrombosis can occur up to several weeks after the discontinuation of heparin therapy.
16 Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin
17 should be evaluated for HIT and HITT.

18 **PRECAUTIONS:**

19 ***General***

20 ***Thrombocytopenia, Heparin-induced Thrombocytopenia (HIT) and Heparin-induced***
21 ***Thrombocytopenia and Thrombosis (HITT)***

22 See **WARNINGS**.

23 ***Heparin Resistance***—Increased resistance to heparin is frequently encountered in fever,

1 thrombosis, thrombophlebitis, infections with thrombosing tendencies, myocardial infarction,
2 cancer and in postsurgical patients.

3
4 *Increased Risk to Older Patients, Especially Women*—A higher incidence of bleeding has
5 been reported in patients, particularly women, over 60 years of age.

6 ***Laboratory Tests***

7 Periodic platelet counts, hematocrits, and tests for occult blood in stool are recommended
8 during the entire course of heparin therapy, regardless of the route of administration (see
9 **DOSAGE AND ADMINISTRATION**).

10 ***Drug Interactions***

11 *Oral Anticoagulants*—Heparin sodium may prolong the one-stage prothrombin time.

12 Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at
13 least five hours after the last intravenous dose or 24 hours after the last subcutaneous dose
14 should elapse before blood is drawn, if a valid prothrombin time is to be obtained.

15
16 *Platelet Inhibitors*—Drugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen,
17 indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-
18 aggregation reactions (the main hemostatic defense of heparinized patients) may induce
19 bleeding and should be used with caution in patients receiving heparin sodium.

20
21 *Other Interactions*—Digitalis, tetracyclines, nicotine or antihistamines may partially
22 counteract the anticoagulant action of heparin sodium. Intravenous nitroglycerin
23 administered to heparinized patients may result in a decrease of the partial thromboplastin
24 time with subsequent rebound effect upon discontinuation of nitroglycerin. Careful
25 monitoring of partial thromboplastin time and adjustment of heparin dosage are
26 recommended during coadministration of heparin and intravenous nitroglycerin.

1 ***Drug/Laboratory Tests Interactions***

2 ***Hyperaminotransferasemia***—Significant elevations of aminotransferase (SGOT [S-AST] and
3 SGPT [S-ALT]) levels have occurred in a high percentage of patients (and healthy subjects)
4 who have received heparin. Since aminotransferase determinations are important in the
5 differential diagnosis of myocardial infarction, liver disease and pulmonary emboli, increases
6 that might be caused by drugs (like heparin) should be interpreted with caution.

7 ***Carcinogenesis, Mutagenesis, Impairment of Fertility***

8 No long-term studies in animals have been performed to evaluate carcinogenic potential of
9 heparin. Also, no reproduction studies in animals have been performed concerning
10 mutagenesis or impairment of fertility.

11 ***Pregnancy***

12 Do not administer Heparin Sodium Injection, USP (porcine), preserved with benzyl alcohol,
13 to pregnant women (see **CONTRAINDICATIONS, *Pregnancy, Nursing Mothers, and***
14 ***Pediatric Use*** and **PRECAUTIONS, *Pediatric Use***). Heparin Sodium Injection, USP
15 (porcine), preservative free, when indicated, should be administered to pregnant women.

16
17 ***Teratogenic Effects: Pregnancy Category C***—

18 Animal reproduction studies have not been conducted with heparin sodium. It is also not
19 known whether heparin sodium can cause fetal harm when administered to a pregnant
20 woman or can affect reproduction capacity. Heparin sodium should be given to a pregnant
21 woman only if clearly needed.

22
23 ***Nonteratogenic Effects***—Heparin does not cross the placental barrier.

24

1 *Nursing Mothers*

2 Do not administer Heparin Sodium Injection, USP (porcine), preserved with benzyl alcohol,
3 to nursing mothers (see **CONTRAINDICATIONS, Pregnancy, Nursing Mothers, and**
4 **Pediatric Use** and **PRECAUTIONS, Pediatric Use**). Heparin Sodium Injection, USP
5 (porcine), preservative free, when indicated, should be administered to nursing mothers.
6 Heparin is not excreted in human milk.

7 *Pediatric Use*

8 See **DOSAGE AND ADMINISTRATION, Pediatric Use**.

9 Do not administer Heparin Sodium Injection, USP (porcine), preserved with benzyl
10 alcohol, to neonates and infants (see **CONTRAINDICATIONS, Pregnancy, Nursing**
11 **Mothers, and Pediatric Use**). Heparin Sodium Injection, USP (porcine), preservative free,
12 when indicated, should be administered to neonates and infants. Benzyl alcohol has been
13 associated with serious adverse events and death, particularly in pediatric patients. The
14 “gaspings syndrome,” (characterized by central nervous system depression, metabolic
15 acidosis, gasping respirations, and high levels of benzyl alcohol and its metabolites found in
16 the blood and urine) has been associated with benzyl alcohol dosages >99mg/kg/day in
17 neonates and low-birthweight neonates. Additional symptoms may include gradual
18 neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin
19 breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse.

20 Although normal therapeutic doses of this product deliver amounts of benzyl alcohol
21 that are substantially lower than those reported in association with the “gaspings syndrome”,
22 the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature
23 and low-birthweight infants, as well as patients receiving high dosages, may be more likely

1 to develop toxicity. Practitioners administering this and other medications containing benzyl
2 alcohol should consider the combined daily metabolic load of benzyl alcohol from all
3 sources.

4 *Geriatric Use*

5 A higher incidence of bleeding has been reported in patients over 60 years of age, especially
6 women (see **PRECAUTIONS, General**). Clinical studies indicate that lower doses of
7 heparin may be indicated in these patients (see **CLINICAL PHARMACOLOGY** and
8 **DOSAGE AND ADMINISTRATION**).

9 **ADVERSE REACTIONS:**

10 *Hemorrhage*

11 Hemorrhage is the chief complication that may result from heparin therapy (see
12 **WARNINGS**). An overly prolonged clotting time or minor bleeding during therapy can
13 usually be controlled by withdrawing the drug (see **OVERDOSAGE**). **It should be**
14 **appreciated that gastrointestinal or urinary tract bleeding during anticoagulant**
15 **therapy may indicate the presence of an underlying occult lesion.** Bleeding can occur at
16 any site but certain specific hemorrhagic complications may be difficult to detect:

17 (a) Adrenal hemorrhage, with resultant acute adrenal insufficiency, has occurred during
18 anticoagulant therapy. Therefore, such treatment should be discontinued in patients who
19 develop signs and symptoms of acute adrenal hemorrhage and insufficiency. Initiation of
20 corrective therapy should not depend on laboratory confirmation of the diagnosis, since any
21 delay in an acute situation may result in the patient's death.

22 (b) Ovarian (corpus luteum) hemorrhage developed in a number of women of reproductive
23 age receiving short- or long-term anticoagulant therapy. This complication, if unrecognized,

1 may be fatal.

2 (c) Retroperitoneal hemorrhage.

3 *Thrombocytopenia, Heparin-induced Thrombocytopenia (HIT) and Heparin-induced*
4 *Thrombocytopenia and Thrombosis (HITT) and Delayed Onset of HIT and HITT*

5 See **WARNINGS**.

6 ***Local Irritation***

7 Local irritation, erythema, mild pain, hematoma or ulceration may follow deep subcutaneous
8 (intrafat) injection of heparin sodium. These complications are much more common after
9 intramuscular use, and such use is not recommended.

10 ***Hypersensitivity***

11 Generalized hypersensitivity reactions have been reported, with chills, fever and urticaria as
12 the most usual manifestations, and asthma, rhinitis, lacrimation, headache, nausea and
13 vomiting, and anaphylactoid reactions, including shock, occurring more rarely. Itching and
14 burning, especially on the plantar side of the feet, may occur (see **WARNINGS** and
15 **PRECAUTIONS**).

16 Certain episodes of painful, ischemic and cyanosed limbs have in the past been
17 attributed to allergic vasospastic reactions. Whether these are in fact identical to the
18 thrombocytopenia-associated complications, remains to be determined.

19 ***Miscellaneous***

20 Osteoporosis following long-term administration of high doses of heparin, cutaneous
21 necrosis after systemic administration, suppression of aldosterone synthesis, delayed
22 transient alopecia, priapism, and rebound hyperlipemia on discontinuation of heparin sodium
23 have also been reported.

1 Significant elevations of aminotransferase (SGOT [S-AST] and SGPT [S-ALT])
2 levels have occurred in a high percentage of patients (and healthy subjects) who have
3 received heparin.

4 **OVERDOSAGE:**

5 *Symptoms*

6 Bleeding is the chief sign of heparin overdosage. Nosebleeds, blood in urine or tarry stools
7 may be noted as the first sign of bleeding. Easy bruising or petechial formations may
8 precede frank bleeding.

9 *Treatment*

10 *Neutralization of Heparin Effect*—When clinical circumstances (bleeding) require reversal of
11 heparinization, protamine sulfate (1% solution) by slow infusion will neutralize heparin
12 sodium. **No more than 50 mg** should be administered, **very slowly**, in any 10 minute
13 period. Each mg of protamine sulfate neutralizes approximately 100 USP heparin units. The
14 amount of protamine required decreases over time as heparin is metabolized. Although the
15 metabolism of heparin is complex, it may, for the purpose of choosing a protamine dose, be
16 assumed to have a half-life of about 1/2 hour after intravenous injection.

17 Administration of protamine sulfate can cause severe hypotensive and anaphylactoid
18 reactions. Because fatal reactions often resembling anaphylaxis have been reported, the drug
19 should be given only when resuscitation techniques and treatment of anaphylactoid shock are
20 readily available.

21 For additional information consult the labeling of Protamine Sulfate Injection, USP
22 products.

23

1 **DOSAGE AND ADMINISTRATION:**

2 **Parenteral drug products should be inspected visually for particulate matter and**
3 **discoloration prior to administration, whenever solution and container permit. Slight**
4 **discoloration does not alter potency.**

5 **Confirm the choice of the correct Heparin Sodium Injection vial prior to**
6 **administration of the drug to a patient (see WARNINGS, *Fatal Medication Errors*).** The
7 1 mL vial must not be confused with a “catheter lock flush” vial or other 1 mL vial of
8 inappropriate strength. Confirm that you have selected the correct medication and strength
9 prior to administration of the drug.

10 When heparin is added to an infusion solution for continuous intravenous
11 administration, the container should be inverted at least six times to ensure adequate mixing
12 and prevent pooling of the heparin in the solution.

13 Heparin sodium is not effective by oral administration and should be given by
14 intermittent intravenous injection, intravenous infusion, or deep subcutaneous (intrafat, i.e.,
15 above the iliac crest or abdominal fat layer) injection. **The intramuscular route of**
16 **administration should be avoided because of the frequent occurrence of hematoma at**
17 **the injection site.**

18 The dosage of heparin sodium should be adjusted according to the patient’s
19 coagulation test results. When heparin is given by continuous intravenous infusion, the
20 coagulation time should be determined approximately every four hours in the early stages of
21 treatment. When the drug is administered intermittently by intravenous injection,
22 coagulation tests should be performed before each injection during the early stages of
23 treatment and at appropriate intervals thereafter. Dosage is considered adequate when the

1 activated partial thromboplastin time (APTT) is 1.5 to 2 times normal or when the whole
2 blood clotting time is elevated approximately 2.5 to 3 times the control value. After deep
3 subcutaneous (intrafat) injections, tests for adequacy of dosage are best performed on
4 samples drawn four to six hours after the injection.

5 Periodic platelet counts, hematocrits and tests for occult blood in stool are
6 recommended during the entire course of heparin therapy, regardless of the route of
7 administration.

8 ***Converting to Oral Anticoagulant***

9 When an oral anticoagulant of the coumarin or similar type is to be begun in patients already
10 receiving heparin sodium, baseline and subsequent tests of prothrombin activity must be
11 determined at a time when heparin activity is too low to affect the prothrombin time. This is
12 about five hours after the last IV bolus and 24 hours after the last subcutaneous dose. If
13 continuous IV heparin infusion is used, prothrombin time can usually be measured at any
14 time.

15 In converting from heparin to an oral anticoagulant, the dose of the oral anticoagulant
16 should be the usual initial amount and thereafter prothrombin time should be determined at
17 the usual intervals. To ensure continuous anticoagulation, it is advisable to continue full
18 heparin therapy for several days after the prothrombin time has reached the therapeutic range.
19 Heparin therapy may then be discontinued without tapering.

20 ***Therapeutic Anticoagulant Effect With Full-Dose Heparin***

21 Although dosage must be adjusted for the individual patient according to the results of
22 suitable laboratory tests, the following dosage schedules may be used as guidelines:

METHOD OF ADMINISTRATION	FREQUENCY	RECOMMENDED DOSE (based on 150 lb [68 kg] patient)
Deep Subcutaneous (Intrafat) Injection	Initial Dose	5,000 units by IV injection, followed by 10,000 to 20,000 units of a concentrated solution, subcutaneously
	Every 8 hours	8,000 to 10,000 units of a concentrated solution
	or Every 12 hours	15,000 to 20,000 units of a concentrated solution
Intermittent Intravenous Injection	Initial Dose	10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
	Every 4 to 6 hours	5,000 to 10,000 units, either undiluted or in 50 to 100 mL of 0.9% Sodium Chloride Injection, USP
Intravenous Infusion	Initial Dose	5,000 units by IV injection
	Continuous	20,000 to 40,000 units/24 hours in 1,000 mL of 0.9% Sodium Chloride Injection, USP (or in any compatible solution) for infusion

1 ***Pediatric Use***

2 Do not administer Heparin Sodium Injection, USP (porcine), preserved with benzyl alcohol,
3 to neonates and infants (see **CONTRAINDICATIONS, *Pregnancy, Nursing Mothers, and***
4 ***Pediatric Use*** and **PRECAUTIONS, *Pediatric Use***). When indicated, Heparin Sodium
5 Injection, USP (porcine), preservative free should be used in neonates and infants.

6 Follow recommendations of appropriate pediatric reference texts. In general, the
7 following dosage schedule may be used as a guideline:

8 Initial Dose: 50 units/kg (IV, infusion)

9 Maintenance Dose: 100 units/kg (IV, infusion) every four hours,
10 or 20,000 units/m²/24 hours continuously

11 ***Geriatric Use***

12 Patients over 60 years of age may require lower doses of heparin.

13 ***Surgery of the Heart and Blood Vessels***

14 Patients undergoing total body perfusion for open-heart surgery should receive an initial dose
15 of not less than 150 units of heparin sodium per kilogram of body weight. Frequently, a dose
16 of 300 units of heparin sodium per kilogram of body weight is used for procedures estimated
17 to last less than 60 minutes, or 400 units per kilogram for those estimated to last longer than
18 60 minutes.

19 ***Low-Dose Prophylaxis of Postoperative Thromboembolism***

20 A number of well-controlled clinical trials have demonstrated that low-dose heparin
21 prophylaxis, given just prior to and after surgery, will reduce the incidence of postoperative
22 deep vein thrombosis in the legs (as measured by the I-125 fibrinogen technique and
23 venography) and of clinical pulmonary embolism. The most widely used dosage has been

1 5,000 units 2 hours before surgery and 5,000 units every 8 to 12 hours thereafter for seven
2 days or until the patient is fully ambulatory, whichever is longer. The heparin is given by
3 deep subcutaneous injection in the arm or abdomen with a fine needle (25 to 26 gauge) to
4 minimize tissue trauma. A concentrated solution of heparin sodium is recommended. Such
5 prophylaxis should be reserved for patients over the age of 40 who are undergoing major
6 surgery. Patients with bleeding disorders and those having neurosurgery, spinal anesthesia,
7 eye surgery or potentially sanguineous operations should be excluded, as well as patients
8 receiving oral anticoagulants or platelet-active drugs (see **WARNINGS**). The value of such
9 prophylaxis in hip surgery has not been established. The possibility of increased bleeding
10 during surgery or postoperatively should be borne in mind. If such bleeding occurs,
11 discontinuance of heparin and neutralization with protamine sulfate are advisable. If clinical
12 evidence of thromboembolism develops despite low-dose prophylaxis, full therapeutic doses
13 of anticoagulants should be given unless contraindicated. All patients should be screened
14 prior to heparinization to rule out bleeding disorders, and monitoring should be performed
15 with appropriate coagulation tests just prior to surgery. Coagulation test values should be
16 normal or only slightly elevated. There is usually no need for daily monitoring of the effect
17 of low-dose heparin in patients with normal coagulation parameters.

18 *Extracorporeal Dialysis*

19 Follow equipment manufacturers' operating directions carefully.

20 *Blood Transfusion*

21 Addition of 400 to 600 USP units per 100 mL of whole blood is usually employed to prevent
22 coagulation. Usually, 7,500 USP units of heparin sodium are added to 100 mL of 0.9%
23 Sodium Chloride Injection, USP (or 75,000 USP units/1,000 mL of 0.9% Sodium Chloride

1 Injection, USP) and mixed; from this sterile solution, 6 to 8 mL are added per 100 mL of
2 whole blood.

3 ***Laboratory Samples***

4 Addition of 70 to 150 units of heparin sodium per 10 to 20 mL sample of whole blood is
5 usually employed to prevent coagulation of the sample. Leukocyte counts should be
6 performed on heparinized blood within two hours after addition of the heparin. Heparinized
7 blood should not be used for isoagglutinin, complement, or erythrocyte fragility tests or
8 platelet counts.

9 **HOW SUPPLIED:**

10 Heparin Sodium Injection, USP (porcine), **preservative free**, is available as follows:

Product No.	NDC No.	
27602	63323-276-02	1,000 USP Heparin Units/mL, 2 mL fill in a 2 mL single dose, flip-top vial, in packages of 25.

11

12 **Preservative Free**

13 Discard Unused Portion.

14 Do not use if solution is discolored or contains a precipitate.

15

16 Heparin Sodium Injection, USP (porcine) contains **benzyl alcohol** and is available as
17 follows:

Product No.	NDC No.	
4710	63323-047-10	5,000 USP Heparin Units/mL, 10 mL fill in a 10 mL multiple dose, flip-top vial, in packages of 25.

1

2 Use only if solution is clear and seal intact.

3

4 Heparin Sodium Injection, USP (porcine) contains **parabens** and is available as follows:

Product No.	NDC No.	
504001*	63323-540-01	1,000 USP Heparin Units/mL, 1 mL fill in a 3 mL vial.
504011	63323-540-11	1,000 USP Heparin Units/mL, 10 mL fill in a 10 mL vial.
504031	63323-540-31	1,000 USP Heparin Units/mL, 30 mL fill in a 30 mL vial.
926201**	63323-262-01	5,000 USP Heparin Units/mL, 1 mL fill in a 3 mL vial.
504201*	63323-542-01	10,000 USP Heparin Units/mL, 1 mL fill in a 3 mL vial.
504207	63323-542-07	10,000 USP Heparin Units/mL, 5 mL fill in a 6 mL vial.
915501**	63323-915-01	20,000 USP Heparin Units/mL, 1 mL fill in a 3 mL vial.

5

6 *Packaged in a plastic or glass vial.

7 **Packaged in a plastic vial.

8 The above products are available in multiple dose, flip-top vials packaged in 25.

9 Do not use if solution is discolored or contains a precipitate.

10 **STORAGE:**

11 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

12

1 **REFERENCES:**

2 1. Tahata T, Shigehito M, Kusuhara K, Ueda Y, et al. Delayed-Onset of Heparin Induced
3 Thrombocytopenia – A Case Report – *J Jpn Assn Torca Surg.* 1992;40(3):110-111.
4 2. Warkentin T, Kelton J. Delayed-Onset Heparin-Induced Thrombocytopenia and
5 Thrombosis. *Annals of Internal Medicine.* 2001;135:502-506.
6 3. Rice L, Attisha W, Drexler A, Francis J. Delayed-Onset Heparin Induced
7 Thrombocytopenia. *Annals of Internal Medicine,* 2002;136:210-215.
8 4. Dieck J., C. Rizo-Patron, et al. (1990). “A New Manifestation and Treatment Alternative
9 for Heparin-Induced Thrombosis.” *Chest* 98(1524-26).
10 5. Smythe M, Stephens J, Mattson. Delayed-Onset Heparin Induced Thrombocytopenia.
11 *Annals of Emergency Medicine,* 2005;45(4):417-419.
12 6. Divgi A. (Reprint), Thumma S., Hari P., Friedman K., Delayed Onset Heparin-Induced
13 Thrombocytopenia (HIT) Presenting After Undocumented Drug Exposure as Post-
14 Angiography Pulmonary Embolism. *Blood.* 2003;102(11):127b.

15



17

18 For Product Inquiry: 1-800-551-7176

19

20 451209

21 Issued: May 2010